Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.51 USD
Change Today -0.02 / -1.31%
Volume 454.3K
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (AVEO) Key Developments

AVEO Pharmaceuticals, Inc. Approves Amendment to the Restated Certificate of Incorporation

AVEO Pharmaceuticals, Inc. announced at the AGM held on May 28, 2015, it has approved amendment to the company's restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.

AVEO Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM

AVEO Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts

AVEO Oncology announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective on May 26, 2015. The new facility consists of approximately 5,000 square feet of office space under flexible lease terms, with no laboratory or vivarium space. The new headquarters represents a reduction of approximately 90% in facilities from its prior Cambridge location at 650 E. Kendall Square.

AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma

AVEO Oncology announced that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The Company previously reported interim median progression free survival (PFS) results of 8.4 months among the 163 patients enrolled in Study 902. Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population. AVEO also announced that it has received a written response from the U.S. Food and Drug Administration (FDA) stating that a phase 3 study outlined by the Company, in patients with RCC who have failed at least two prior regimens, including VEGF therapy, “may support AVEO’s proposed indication for tivozanib in the 3rd line setting.” In response to whether the study, together with the TIVO-1 study, would be sufficient to support licensure of tivozanib as a treatment for advanced RCC, the FDA indicated: “whether the results from this study can support AVEO’s proposal for tivozanib in the first line setting is a review issue. The study design shared with the FDA is a randomized, controlled, multi-center, open-label Phase 3 study of approximately 314 subjects randomized 1:1 to receive either tivozanib or sorafenib. Subjects enrolled in the study may include those who have received prior immunotherapy, including immune checkpoint (PD-1) inhibitors, reflecting a potentially evolving treatment landscape. The primary objective of the study would be PFS. Secondary objectives would include OS and objective response rate (ORR) as well as safety and pharmacokinetic endpoints.

AVEO Oncology Announces Unaudited Consolidated Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Third Quarter of 2016

AVEO Oncology announced unaudited consolidated earnings results for the first quarter of 2015. The company reported a wider-than-expected loss for the first quarter of 2015, but beat the analyst estimate by $0.04 per share. The company reported a net loss of $10.9 million, or $0.21 per share compared to for the same quarter last year, reported a loss of $6.4 million, or $0.12 per share. As a result of an additional one-time recognition of $14.1 million of previously deferred revenue as a result of the modification of Aveo's arrangement with Biogen Idec (BIIB), revenue was only $134,000 versus $15.3 million for first quarter of 2014. Total revenue was $10.283 million against $21.181 million a year ago. Loss from operations was $10.149 million against $5.892 million a year ago. The increase in the net loss is primarily driven by the additional one-time recognition of previously deferred revenue during first quarter of 2014, partially offset by the decrease in R&D and G&A expense. Based on its current operating plan, the company expects its $39.1 million in cash resources as of March 31, 2015 will be sufficient to fund operations into the third quarter of 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVEO:US $1.51 USD -0.02

AVEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.76 USD -0.05
Bristol-Myers Squibb Co $64.30 USD -1.68
Exelixis Inc $5.44 USD -0.15
GlaxoSmithKline SAE £11.50 EGP 0.00
Takeda Pharmaceutical Co Ltd ¥6,068 JPY -40.00
View Industry Companies
 

Industry Analysis

AVEO

Industry Average

Valuation AVEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.1x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.